Copy

Autoimmunity
January 2019
ESL Biosciences, in partnership with Euroimmun AG, offer the most comprehensive range of diagnostic products and services for the determination of autoantibodies

NEW!
EUROIMMUN Anti-Zinc Transporter 8 ELISA

A Complementary Test for Detecting Diseases-Associated Antibodies in Diabetes Mellitus Type I

Autoantibody-mediated destruction of beta cells starts years before the manifestation of diabetes mellitus type I. The risk of suffering from type I diabetes increases with the number of specific autoantibodies detected in the serum, while occurrence of these antibodies at young age also indicates increased risk of disease development.

Anti-Zinc transporter 8 (ZnT8) antibodies are directed against ZnT8 that are expressed on the cell membrane of secretary granules in the beta cells.
Key Findings on Anti-ZnT8 Antibodies in Recent Studies:
  • High prevalence in patients at onset of diabetes mellitus type I
    • up to 70% in pediatric patients
    • around 50 % in adult patients
    • about 30% in LADA patients
  • Children with positive anti-ZnT8 antibody findings are more likely to develop diabetes mellitus type I
  • Presence of anti-ZnT8 antibodies may predict the transmission of LADA into insulin-dependent diabetes
  • Anti-AnT8 antibodies are found in 26% of type I diabetes patients in whom no autoantibody against GAD, IA2 or insulin was found
The new EUROIMMUN Anti-ZnT8 ELISA is an excellent complement to the existing EUROIMMUN portfolio for the detection of autoantibodies in type I diabetes. The combined detection of antibodies against ZnT8, GAD, IA2 and insulin increases the detection rate of diabetes mellitus type I to 98% at disease onset.
 
Please contact your area ESL sales representatives for more information on EUROIMMUN Anti-ZnT8 ELISA and the EUROIMMUN  portfolio for diagnosis of diabetes mellitus type I
NZ
NZ
Australia
Australia
Website
Website
Twitter
Twitter
Facebook
Facebook
LinkedIn
LinkedIn
Google+
Google+
Copyright © 2019 ESL Biosciences (New Zealand) Limited. All rights reserved.
unsubscribe from this list  |  update subscription preferences